Atlas Trials

Refractory Chronic Myelomonocytic Leukemia

19 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Refractory Chronic Myelomonocytic Leukemia

RecordFirmDate
Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Who Have Failed Therapy With Hypomethylating Agents (NCT05030675)M.D. Anderson Cancer Center2021-08-13
FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies (NCT04891757)Foghorn Therapeutics Inc.2021-06-14
DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia (NCT04752163)M.D. Anderson Cancer Center2021-03-25
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia (NCT04375631)Fred Hutchinson Cancer Center2020-12-03
Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT04550442)M.D. Anderson Cancer Center2020-09-04
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia (NCT04239157)M.D. Anderson Cancer Center2020-08-25
Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome (NCT04487106)M.D. Anderson Cancer Center2020-07-21
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (NCT03878524)OHSU Knight Cancer Institute2020-04-01
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm (NCT04140487)M.D. Anderson Cancer Center2019-12-17
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia (NCT03896269)M.D. Anderson Cancer Center2019-05-14
A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies (NCT03886831)Prelude Therapeutics2019-02-11
Hu8F4 in Treating Patients With Advanced Hematologic Malignancies (NCT02530034)M.D. Anderson Cancer Center2019-01-31
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome (NCT03404193)M.D. Anderson Cancer Center2018-01-18
Quizartinib With Azacitidine or Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome (NCT01892371)M.D. Anderson Cancer Center2013-11-12

Track Refractory Chronic Myelomonocytic Leukemia automatically

Every clearance here is in the API, with alerts when new ones post.